CoChat

Preliminary Observations on the Effectiveness of Levetiracetam in the Open Adjunctive Treatment of Refractory Bipolar Disorder

Post, Robert M., Altshuler, Lori L., Frye, Mark A., Suppes, Trisha, McElroy, Susan L., Keck, Paul E., Leverich, Gabriele S., Kupka, Ralph, Nolen, Willem A., Luckenbaugh, David A., Walden, Jorg, Grunze, Heinz · 2005 · The Journal of Clinical Psychiatry
Cited by 69

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: Levetiracetam is a recently approved, well-tolerated anticonvulsant with a unique mechanism of action yielding efficacy in treatment-refractory seizure disorders and positive effects in an animal model of mania. Given the effectiveness of a range of other anticonvulsants in bipolar disorder, we sought to evaluate levetiracetam in patients with treatment-resistant illness. METHOD: Thirty-four patients received 500 to 1000 mg of levetiracetam titrated to a target dose of 2000 mg/day (maximum dose = 3000 mg/day) as open, adjunctive treatment for clinically significant symptoms of depression (N = 13), mania (N = 7), or cycling (N = 14) despite ongoing treatment with mood stabilizers. Inventory for Depressive Symptomatology-Clinician version (IDS-C), Young Mania Rating Scale (YMRS), and Clinical Global Impressions scale for use in Bipolar Illness ratings were completed at each visit for 8 weeks, and partial responders were offered continuation treatment. Data were collected from July 2001 to December 2002. RESULTS: Five of 16 (31%; 13 depressed, 3 cycling) patients with initial depressive symptoms met the criterion for remission (IDS-C score of < or = 13) at last observation. All of these patients were less severely ill at baseline, whereas none of those more severely depressed at baseline responded. The majority of the 16 patients (7 manic, 9 cycling) with manic symptoms at baseline showed improvement in the YMRS in the first 2 weeks. While 7 of the 16 (44%) patients met the criterion for manic response and remission at last observation, 4 showed intervening periods of moderate to marked exacerbation. Levetiracetam was weight neutral. CONCLUSION: Other pilot trials should explore possible areas of psychotropic action of levetiracetam prior to the conduct of more controlled clinical trials.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.4088/jcp.v66n0314

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 69

Metadata

Authors
Post, R. M., Altshuler, L. L., Frye, M. A., Suppes, T., McElroy, S. L., Keck, P. E., Leverich, G. S., Kupka, R., Nolen, W. A., Luckenbaugh, D. A., Walden, J., & Grunze, H.
Venue
The Journal of Clinical Psychiatry
Published
2005-03-15
Volume
66
Issue
03
Pages
370-374
ISSN
0160-6689 (ISSN-L)
OpenAlex
W2136030099
Cited by
69
References
3
FWCI
4.40
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Preliminary Observations on the Effectiveness of Levetiracetam in the Open Adjunctive Treatment of Refractory Bipolar Disorder. https://app.cochat.ai/papers/10.4088/jcp.v66n0314
The paper
Post, R. M., Altshuler, L. L., Frye, M. A., Suppes, T., McElroy, S. L., Keck, P. E., Leverich, G. S., Kupka, R., Nolen, W. A., Luckenbaugh, D. A., Walden, J., & Grunze, H. (2005). Preliminary Observations on the Effectiveness of Levetiracetam in the Open Adjunctive Treatment of Refractory Bipolar Disorder. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.v66n0314

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.